🔎 Trials Near Me

Akèy › Amiloidoz › Oregon › Portland

Etid klinik pou Amiloidoz nan Portland, OR

6 etid pou Amiloidoz ap chèche patisipan nan sit nan ak bò kote Portland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Ap rekriteEtid obsèvasyon
  • Research Site, Portland
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT06465810

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Ap rekriteFaz 3
  • Clinical Trial Site, Portland
Laj 18 a 85 · Tout sèks · Mizajou Sep 16, 2026 · NCT07052903

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Ap rekriteFaz 3
  • Oregon Health & Science University, Portland
Laj 18 a 75 · Tout sèks · Mizajou Aug 4, 2026 · NCT06563895

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Ap rekriteFaz 1/2
  • Oregon Medical Research Center /ID# 255119, Portland
Laj 18 ak plis · Tout sèks · Mizajou May 13, 2026 · NCT06158854

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

Ap rekriteFaz 2
  • Oregon Health & Science University, Portland
Laj 40 a 90 · Tout sèks · Mizajou Apr 13, 2026 · NCT05758493

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Ap rekriteFaz 3
  • Oregon Health and Science University (OHSU), Portland
Laj 18 a 90 · Tout sèks · Mizajou Mar 27, 2026 · NCT06128629

Etid Amiloidoz nan lòt vil

Lòt etid nan Portland

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.